App aims to improve heart failure management through daily tracking
NCT ID NCT06750549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a mobile app designed to help people with heart failure monitor their blood pressure, weight, and heart rate daily. The app also tracks symptoms and medications, sharing the data with doctors to guide treatment. Researchers wanted to see if using the app leads to better medication use and improved quality of life over 90 days. The study involved 134 participants recently hospitalized for heart failure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ENGAGE-HF mobile application (a device for self-monitoring and clinician feedback)
- What this could lead to
- If successful, this app could help heart failure patients better manage their condition and improve medication use and quality of life.
- What could go wrong
- This is a small, completed study (134 participants) testing a monitoring tool, not a treatment. Results may not apply to all heart failure patients, and the app itself does not directly treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
134 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
May 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of heart failure * Last left ventricular ejection fraction within 2 years \< 50% based on echocardiogram, MRI, CT, or nuclear perfusion and, if no ejection fraction documented, then clinical documentation of heart failure with reduced ejection fraction * Currently admitted with upcoming discharge or discharged from hospital within the prior 4 weeks * At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or at \< 50% of target dose at time of enrollment Exclusion Criteria: * Receives dialysis * Inotropic therapy after hospitalization * History of a prior solid organ transplant or actively listed on heart transplant waiting list * History of left ventricular assist device implantation * Cardiac amyloidosis * Currently pregnant or intends to become pregnant during the study period * Life expectancy estimated less than 6 months related to cardiac or non-cardiac comorbidities as per investigator's judgment * Actively enrolled in hospice or comfort care * Currently participating in an investigational device or drug study or having participated in such a study 30 days prior to screening * Subject without a compatible smartphone * Subject not proficient with written and spoken English * Any other disorder or condition that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion * Participant has diminished decision-making capacity * Admitted to or planned discharge to a skilled nursing facility or rehabilitation facility (acute or subacute)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford Cardiovascular Clinic
Stanford, California, 94305, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
U-M Frankel Cardiovascular Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?